Some patient advocacy groups opposing Medicare changes have received funding from pharma companies in the past; new techniques allow scientists to target individual cells for analysis; rural nursing homes continue to close.
Numerous patient advocacy groups recently appeared in nationwide advertisements opposing a Trump administration proposal that could limit the drugs required to be covered by Medicare. Nearly half of the groups representing patients have received payments, totaling more than $58 million in 2015 alone, from pharmaceutical companies, Kaiser Health News reported. While these groups continue to lobby Congress and the administration, experts have raised concerns regarding whether their financial ties could push them to put drugmakers’ interests ahead of the patients they represent.
Previously, studying key traits of cells required analysis of vast tissue samples, resulting in a scattered average of results from numerous cell types. Recently, scientists have discovered new techniques that allow them to directly study DNA codes, the activity of genes, and other traits of individual cells, the Associated Press reported. These methods have become widespread, revealing new details about the body and potentially allowing every human cell type to be catalogued.
Many residents have been forced to relocate as nursing homes continue to close in rural towns across the nation, mainly for financial reasons, and more individuals, swayed by changing health policies, are encouraged to live in their own homes with help from caregivers. Some residents of these nursing homes have been transferred long distances from their prior locations, making trips to visit them difficult or impossible and isolating them from spouses, friends, relatives, and religious groups they have known throughout their lives, The New York Times reported.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen